The Impact of State Medicaid Eligibility and Benefits Policy on Neonatal Abstinence Syndrome Hospitalizations

Area of Science:

• Public Health
• Health Policy
• Neonatal Medicine

Background:

• Opioid misuse during pregnancy is a growing concern, leading to increased rates of neonatal abstinence syndrome (NAS).
• Existing policies for treating pregnant women with opioid use disorder are often unclear and inconsistently applied.
• Effective interventions are crucial to mitigate the adverse effects of NAS on newborns.

Purpose of the Study:

• To investigate the impact of state Medicaid policies on neonatal abstinence syndrome (NAS) hospitalizations.
• To determine if the Affordable Care Act's (ACA) Medicaid expansion influenced NAS rates in relation to medication coverage.
• To understand the nuanced relationship between health insurance policy and NAS outcomes.

Main Methods:

• Utilized a difference-in-differences research design.
• Analyzed national pediatric inpatient discharge records.
• Examined state-level Medicaid policies regarding coverage for buprenorphine and methadone for opioid use disorder.

Main Results:

• In states where Medicaid covered both buprenorphine and methadone, the ACA's Medicaid expansion was associated with a reduction in Medicaid-covered NAS hospitalizations.
• Medicaid expansion did not show a significant effect on NAS hospitalizations in states without comprehensive medication coverage.
• Findings highlight the importance of specific policy provisions in mitigating NAS.

Conclusions:

• Medicaid policies covering clinically-recommended medications for opioid use disorder are crucial for reducing NAS hospitalizations.
• The ACA's Medicaid expansion demonstrated a positive impact on NAS rates, but only in specific policy contexts.
• Addressing opioid misuse in pregnant women requires tailored policy considerations, including robust medication access through Medicaid.